Thursday, 12 December 2019

Y-Biologics, Dualogics to co-develop antibody against cancer

17 June 2019 | News

The two companies plan to jointly develop lead candidates and develop drugs.

image credit-

image credit-

Y-Biologics, a South Korea based human antibody company, has signed an agreement with Dualogics, a dual antibody company based in Durham, North Carolina, to co-develop a new immunochemistry double antibody.

Under the terms of the agreement, Y-Biologics will develop a number of new immunotherapy dual antibodies using antibodies derived from its own human antibody library, 'Y-max ABL', and Orthomab, dual antibody platform dual antibody platform technology. The two companies plan to jointly develop lead candidates and develop drugs. However, financial conditions were not disclosed.

"We are delighted to demonstrate the superiority of the unique human antibody library, Y-max ABL, which enables rapid identification of a wide range of antibodies through this agreement," said Park Young-woo, president of Y-Bio. "We are pleased to collaborate with dual. We will open a new chapter in the development of our immunocompromised double antibody."

Ryan Hallet, CEO of Dual Logics, said, "We are very pleased to work with Y-Bio, a company that has established expertise in the antibody field and is able to quickly identify a variety of new antibodies through its own library." "This collaboration based on Dual Logics' expertise in the field of dual antibodies and the ability to detect antibodies in Y-Bio will be an important opportunity to provide new treatments to patients suffering from cancer," he said. 


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls